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To alter the natural history of congestive heart failure and change 
the poor prognosis for patients with this condition will require new 
insights into its pathogenesis as well as the development of strate- 
gies to alter the neurohumeral and serum electrolyte abnormalities 
associated with congestive heart failure, which are often exagger- 
ated by current therapeutic approaches. Although improvement in 
hemodynamics and exercise tolerance in patients with congestive 
heart failure remains important, the emphasis of therapeutic goals 
should be shifted to prevent further cardiac deterioration and to pre- 
vent sudden cardiac death. The use of converting enzyme inhibitors 
holds promise for a beneficial effect on the altered hemodynamic, 
electrolyte, and nr+urohumeral abnormalities associated with con- 
gestive heart failure. If further prospective randomized trials con- 
firm the beneficial effects of these agents in reducing the mortality 
rate among patients with congestive heart failure, it is likely that 
these benefits will have stemmed from their effects on neuro- 
humeral factors and serum electrolyte abnormalities rather than 
from their effects on hemodynamics. 
McKee et al [I] in 1971 on the basis of their observations in the Framing- 
ham study found that, despite the use of digitalis and diuretics, the proba- 
bility of dying within five years from the onset of congestive heart failure 
was 62 percent for men and 48 percent for women. They stated that 
“despite earlier recognition and increasingly sophisticated and potent 
treatment of congestive heart failure its clinical course and prognosis 
remain surprisingly grim and not much better than cancer in general.” 
Since the 196Os, the period during which the patients in the Framing- 
ham study were followed, much has changed. The most common cause 
of congestive heart failure in the Framingham study was hypertensive 
heart disease. Advances in understanding the pathogenesis and therapy 
of hypertension over the past five years have made this entity a less 
common cause of congestive heart failure. The incidence of hospital dis- 
charges for congestive heart failure per 100,000 population, however, 
continues to rise [2]. The major causes of congestive heart failure in the 
1980s are ischemic heat-t disease and idiopathic cardiomyopathy. Rapid 
progress in the development of noninvasive diagnostic techniques, in- 
cluding echocardiography, radionuclide ventriculography, computed to- 
mographic imaging, and most recently nuclear magn&ic resonance im- 
aging, has improved the diagnostic evaluation of patients with congestive 
heart failure. New forms of therapy introduced over the past decade in- 
cluding vasodilators, nonglycoside inotropic agents, and novel antiar- 
rhythmic agents have found wide application in patients with congestive 
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heart failure. Despite these advances in diagnosis and 
therapy, the statement made by McKee et al [I] regarding 
the prognosis of patients with congestive heart failure un- 
fortunately remains true. Studies in the 1980s utilizing cur- 
rent diagnostic and therapeutic techniques reveal a mor- 
tality rate among patients with congestive heart failure 
similar to that reported by McKee et al [I] more than 25 
years ago. Wilson et al [3] noted that the mortality rate 
among patients with this condition is similar regardless of 
whether the etiology is due to ischemic heart disease 
or idiopathic cardiomyopathy. Approximately half of the 
deaths due to congestive heart failure result from progres- 
sive congestive heart failure and the other half from sud- 
den cardiac death [3]. 
In a recent survey of all published randomized trials of 
direct-acting arterial and/or venous dilators, Furberg and 
Yusuf [4] failed to find any significant trend indicating a 
reduction in the mortality rate. Similarly, there are no data 
suggesting that the newer inotropic agents, either beta 
agonists or phosphodiesterase inhibitors, have favorably 
altered mortality. In fact, what little data that are available 
concerning inotropic agents suggest the possibility of an 
adverse effect upon mortality [5]. 
In some studies, ambulatory electrocardiographic re- 
cording and/or electrophysiologic testing have been 
shown to predict sudden cardiac death in patients with 
chronic congestive heart failure [6]. There is, however, no 
convincing data to suggest that suppression of ventricular 
ectopic activity by antiarrhythmic therapy has reduced the 
incidence of sudden cardiac death in patients with con- 
gestive heart failure due to ischemic heart disease or idio- 
pathic cardiomyopathy. The antiarrhythmic agents that 
have been evaluated have been found to be either poorly 
tolerated and/or to have a proarrhythmic effect. The only 
therapy suggested to reduce mortality in patients with 
chronic congestive heart failure are the converting en- 
zyme inhibitors [4]. Although data on the effectiveness of 
these agents in reducing mortality in patients with conges- 
tive heart failure are as yet limited and only suggestive, 
their mechanism of action and effects on serum electro- 
lytes and neurohumeral factors offer promise for the fu- 
ture. Several large randomized trials of converting en- 
zyme inhibitors in patients with congestive heart failure 
are currently under way and should over the next several 
years provide important data on the natural history of pa- 
tients with congestive heart failure as well as a better as- 
sessment of the role of these drugs in congestive heat-t 
failure. 
ELECTROLYTE ABNORMALITIES IN PATIENTS WITH 
CONGESTIVE HEART FAILURE 
The need for potassium replacement in patients with con- 
gestive heart failure, many of whom are receiving potent 
diuretics, is well known, as is the role of hypokalemia in 
predisposing to arrhythmias in patients taking digitalis. 
SYMPOSIUM ON CONVERTING ENZYME INHIBITORS-PITT 
Despite this knowledge and the extensive use of potas- 
sium supplements, the incidence of hypokalemia in pa- 
tients with congestive heart failure remains disappoint- 
ingly high. Johansson [7] found that in the 1980s the inci- 
dence of hypokalemia in patients with congestive heart 
failure who were taking diuretics was 20 to 25 percent. In 
other reports, the incidence of hypokalemia in patients 
taking diuretics for congestive heart failure is as high as 
65 percent [8]. Johannson emphasized that the currently 
available potassium supplements are often ineffective in 
correcting diuretic-induced hypokalemia. The importance 
of hypokalemia in predisposing toward ventricular arrhyth- 
mia has recently been re-emphasized by Nordrehaug et al 
[9] who found a high correlation between serum potas- 
sium levels and the probability of ventricular tachycardia 
in patients with acute myocardial infarction. The impor- 
tance of potassium replacement in preventing sudden 
cardiac death is emphasized by the findings of Bet-tuso et 
al [lo], which showed that potassium replacement was 
effective without concomitant antiarrhythmic therapy in 
preventing sudden cardiac death in patients who had a 
previous diagnosis of sudden death associated with hypo- 
kalemia. 
Although the importance of detecting and correcting 
diuretic-induced hypokalemia in patients with congestive 
heart failure is well recognized, the role of magnesium is 
less well appreciated. In patients with congestive heart 
failure, skeletal muscle potassium was found to be re- 
duced to 40.5 i 5.02 mmimol 100 g, compared with 
44.6 +- 4.0 in control patients. Skeletal muscle magne- 
sium was also reduced to 3.95 rF- 0.40 mm/ml 100 g, com- 
pared with 4.34 +- 0.29 in control patients [8]. A good cor- 
relation has also been found between serum magnesium 
levels and the incidence of ventricular ectopic beats 
[11,12]. In some patients with congestive heart failure, 
hypokalemia can only be corrected after administration of 
magnesium 1131. Burch and Giles [14] reviewed the car- 
diac causes of hypomagnesemia and the role of hypo- 
magnesemia in predisposing toward ventricular arrhyth- 
mias and sudden cardiac death a decade ago. Diuretics 
such as furosemide cause a loss of magnesium as well as 
potassium. Congestive heart failure alone without diuretic 
therapy may also lead to hypomagnesemia. Hypomag- 
nesemia, as well as hypokalemia, have been implicated in 
the occurrence of torsade de pointes. Kay et al [15] de- 
scribed 32 patients with torsade de pointes and noted pro- 
longation of the QTc interval prior to development of tor- 
sade de pointes in 30 of the 32. The prolonged QTc inter- 
val was often associated with hypokalemia and/or hypo- 
magnesemia. The episodes of torsade de pointes oc- 
curred in conjunction with the use of antiarrhythmic agents 
despite the fact that the blood levels of the antiarrhythmic 
agents were within the therapeutic range. The develop- 
ment of torsade de pointes was not benign in that death in 
five of the 32 patients was a direct result of this arrhyth- 
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mia. This study emphasizes the danger of administering 
antiarrhythmic agents to patients with congestive heart 
failure who frequently have hypokalemia and/or hypo- 
magnesemia. Hypokalemia is often considered of impor- 
tance when the serum potassium level is below 3.4 meqi 
liter. However, in patients receiving antiarrhythmic agents, 
torsade de pointes has been found to occur at potassium 
levels of 3.9 meqiliter or less [16]. This has led to the 
suggestion that in patients receiving antiarrhythmic 
agents, serum potassium levels should be maintained at 
4.0 meq/liter or above. In fact, the determination of potas- 
sium and/or magnesium depletion by plasma sampling 
detects only a fraction of the patients with total body po- 
tassium and/or magnesium depletion. 
The frequent occurrence of hypokalemia and/or hypo- 
magnesemia in patients with congestive heart failure 
treated with furosemide and other potassium-like diuretics 
and the increasing recognition of the dangers of hypokale- 
mia and/or hypomagnesemia in predisposing to ventricu- 
lar tachycardia make more intensive efforts to detect and 
correct hypokalemia and hypomagnesemia in these pa- 
tients important. The maintenance of serum potassium 
and magnesium levels by the use of converting enzyme 
inhibitors may be an important part of their beneficial role 
in patients with congestive heart failure and may explain 
their ability to improve mortality [3]. Potassium-sparing 
diuretics and/or converting enzyme inhibitors have as yet 
been underutilized in patients with congestive heart fail- 
ure. Although hyperkalemia is a recognized risk of using 
potassium-sparing diuretics, the failure of current strate- 
gies to protect against hypokalemia and/or hypomagne- 
semia and the association of these electrolyte abnormali- 
ties with ventricular arrhythmias suggests that hypokale- 
mia rather than hyperkalemia may be a greater risk to the 
patient with congestive heart failure. 
NEUROHUMERAL ABNORMALITIES IN CONGESTIVE 
HEART FAILURE 
Plasma norepinephrine levels have been found to be ele- 
vated in patients with congestive heart failure and to indi- 
cate a poor prognosis. Patients with plasma norepineph- 
rine levels above 800 pg/ml have a high mortality rate of 
approximately 90 percent in two years [I 71. Although the 
elevated levels of norepinephrine may only reflect the 
underlying ventricular dysfunction [18], they may contrib- 
ute to the risk of death in patients with congestive heart 
failure by predisposing to myocardial cell necrosis and, 
hence, progression to cardiac failure and/or hypokalemia 
and, therefore, sudden death. Direct-acting vasodilators, 
which may further increase catecholamine concentration 
as a result of reflex sympathetic activation, might be detri- 
mental. The ability of converting enzyme inhibitors to 
cause vasodilatation without a secondary increase in nor- 
epinephrine levels may be an important factor in their ben- 
eficial effect in patients with congestive heart failure. 
Among other neurohumeral abnormalities in congestive 
heart failure, plasma renin levels are elevated. During 
exercise, plasma renin levels increase significantly in pa- 
tients with congestive heart failure, compared with levels 
in normal control subjects [19]. The activation of the renin- 
angiotensin system during exercise in patients with con- 
gestive heart failure could lead to an increased afterload 
and further left ventricular compromise. Of greater con- 
cern is the fact that the activation of the renin-angiotensin 
system results in catecholamine stimulation and hypokal- 
emia, both of which, as mentioned earlier, may contribute 
to the increased risk associated with congestive heart fail- 
ure. The ability of converting enzyme inhibitors to inhibit 
the formation of renin and therefore to protect against fur- 
ther increases in plasma catecholamines and hypokale- 
mia may in part account for their beneficial effects in pa- 
tients with congestive heart failure. The beneficial effects 
of converting enzyme inhibitors on plasma renin levels in 
patients with congestive heart failure is in contrast to the 
effect of furosemide, which causes a significant increase 
in the plasma renin level with potential adverse hemody- 
namic, neurohumeral, and electrolyte effects. The ability 
of furosemide and other diuretics to cause hypokalemia 
and/or hypomagnesemia and hyperreninemia in patients 
with congestive heart failure may be an important reason 
for our inability to alter mortality rates in these patients. 
Another neurohumeral abnormality in patients with con- 
gestive heart failure is an elevated plasma level of atrial 
naturetic factor [20]. The level of plasma atrial naturetic 
factor appears to be increased in patients with congestive 
heart failure in response to atrial distension. This factor, 
when given intravenously to patients with congestive 
heart failure, causes an increase in cardiac output and 
naturesis [21]. The fact that patients with severe conges- 
tive heart failure have markedly elevated levels of atrial 
naturetic factor [20] suggests tolerance to the effects of 
this factor and/or the development of other mechanisms 
that inhibit naturesis. The pathogenesis and prognostic 
role of atrial naturetic factor in patients with congestive 
heart failure and the role of converting enzyme inhibitors 
in relation to this factor remain to be determined. 
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